← Back to Search

Alkylating Agent

Olaparib plus carboplatin and paclitaxel for Ovarian Cancer

Phase 1 & 2
Waitlist Available
Led By Saul Rivkin, MD
Research Sponsored by Swedish Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured by ct scans performed every 8 weeks while receiving treatment. (anticipated time of 6 months)
Awards & highlights

Study Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of the investigational agent, olaparib, to give in combination with carboplatin and paclitaxel in patients with relapsed ovarian cancer or uterine cancer. Furthermore, the investigators intend to study the safety and tolerability of the study treatment, response to treatment, time to disease progression, and overall survival.

Eligible Conditions
  • Ovarian Cancer
  • Uterine Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured by ct scans performed every 8 weeks while receiving treatment. (anticipated time of 6 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured by ct scans performed every 8 weeks while receiving treatment. (anticipated time of 6 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Dose Limiting Toxicity (DLT)
Secondary outcome measures
Number of Reported Adverse Events
Other outcome measures
Overall Survival
Response to Therapy
Time to Progression

Trial Design

1Treatment groups
Experimental Treatment
Group I: Olaparib plus carboplatin and paclitaxelExperimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
FDA approved
Paclitaxel
FDA approved
Olaparib
FDA approved

Find a Location

Who is running the clinical trial?

Swedish Medical CenterLead Sponsor
53 Previous Clinical Trials
8,242 Total Patients Enrolled
AstraZenecaIndustry Sponsor
4,267 Previous Clinical Trials
288,606,929 Total Patients Enrolled
48 Trials studying Ovarian Cancer
23,850 Patients Enrolled for Ovarian Cancer
Saul Rivkin, MDPrincipal InvestigatorSwedish Medical Center Cancer Institute
1 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
2012. "Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01650376.
All > Acl > Lynparza
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top